A. Lambiase

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

Giampietro Gasparini, Massimo Gion, Luigi Mariani et al. · Breast Cancer Research and Treatment · 2006 · 138 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma

Emilio Bajetta, Maria Di Bartolomeo, Luigi Mariani et al. · Cancer · 2004 · 135 citations · Full text

Medicine, Oncology, Pharmacology +11

Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory

Giacomo Oliveira, Eliana Ruggiero, Maria Teresa Lupo Stanghellini et al. · Science Translational Medicine · 2015 · 113 citations

Life Sciences, Cell Biology, Immunology +12

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

Vanesa Gregorc, Paolo Andrea Zucali, Armando Santoro et al. · Journal of Clinical Oncology · 2010 · 109 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

Vanesa Gregorc, Armando Santoro, E. Bennicelli et al. · British Journal of Cancer · 2009 · 85 citations · Full text

Medicine, Oncology, Pharmacology +17